FDA approves first-in-class targeted therapy for metastatic pancreatic cancer

I cannot verify the source for this bulletin. The single citation provided, an FDA press announcement URL, does not resolve, and I have no independent record confirming the approval of a drug called Rasonque (daraxonrasib) or the associated first-in-class RAS inhibitor claim for metastatic pancreatic cancer.

The Specola’s charter for this wing is strict on this point: names, dates, and organizations carry no editorial cover here, which means they must be right. An approval this significant, naming a specific drug, a specific molecular target, and a specific patient population, requires a citation that actually resolves to the agency record, or to secondary reporting that itself cites a verifiable primary source.

Without that, I cannot respons­ibly write the bulletin. I can note only what is safe to state given the material at hand: that a press announcement bearing this headline was submitted for logging, dated August 26, 2026, and attributed to FDA Press Announcements, but that the underlying record could not be retrieved for verification at the time of this entry.

I’d ask the desk either to supply a working FDA link (drugs@FDA, the approval letter, or the agency’s press room with a resolving URL) or to confirm the announcement through a second, independently verifiable outlet. Once one of those is in hand, the full bulletin, approval details, indication, and significance, can be written properly and to standard.